Ustekinumab

證據等級: L5

預測適應症: 10 個

Ustekinumab: From Psoriasis to Dermatitis (Atopic Dermatitis)

One-Sentence Summary

Ustekinumab is an IL-12/IL-23 p40 antagonist monoclonal antibody; per literature evidence in this pack it is already approved for psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis, though no formal German (BfArM) licensing data is available in this evidence pack. The TxGNN model predicts it may be effective for Dermatitis (Atopic Dermatitis), supported by 7 clinical trials (including 2 completed Phase 2 RCTs) and 20 publications. However, a Blocking data gap on TFDA/BfArM safety labeling means this candidate cannot yet complete a safety pre-assessment.

Quick Overview

Item	Content
Original Indication	Not documented in the Germany regulatory data provided (0 licenses on file). Per literature evidence (PMID 36208443), ustekinumab is elsewhere approved for psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis
Predicted New Indication	Dermatitis (Atopic Dermatitis)
TxGNN Prediction Score	99.99%
Evidence Level	L2
Germany Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data from DrugBank is not available in this evidence pack (data gap). However, the literature evidence collected here consistently describes ustekinumab as a fully human IgG1 monoclonal antibody that binds the shared p40 subunit of interleukin (IL)-12 and IL-23, thereby suppressing Th1, Th17 and Th22 pathway activation (PMID 27304428, PMID 36208443). This class of biologic is already used to treat inflammatory diseases with a strong Th17/Th22 signature, most notably psoriasis and psoriatic arthritis.

Atopic dermatitis shares overlapping Th17/Th22-driven inflammatory pathology with psoriasis, even though the two conditions are clinically distinct (Th2-dominant in AD vs. Th17-dominant in psoriasis). Several groups have therefore tested whether blocking IL-12/23 with ustekinumab also benefits AD patients, reasoning that Th22 suppression in particular could reduce epidermal hyperplasia and barrier dysfunction seen in chronic AD lesions (PMID 27745907 demonstrated measurable down-regulation of Th2/Th22 markers with ustekinumab in severe AD).

Results across the identified studies are mixed — some placebo-controlled trials (e.g., the Japanese Phase 2 study, PMID 28338223) showed only modest separation from placebo, and systematic reviews/meta-analyses (PMID 33074565, PMID 29098604) conclude that evidence for biologics targeting IL-12/23 in AD is still inconsistent compared with IL-4/IL-13-targeted agents. This tempers, but does not eliminate, the mechanistic plausibility of the TxGNN prediction.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01806662	Phase 2	Completed	32	Randomized pilot study of ustekinumab in chronic atopic dermatitis patients with sub-optimal response to prior therapy
NCT01945086	Phase 2	Completed	79	Randomized, double-blind, placebo-controlled study of two ustekinumab doses in Japanese adults with severe atopic dermatitis
NCT02074982	Phase 3	Completed	676	CLEAR trial — secukinumab vs. ustekinumab in moderate-to-severe plaque psoriasis (original indication comparator study, not AD)
NCT01356758	N/A	Completed	126	Cardiovascular risk assessment in severe psoriasis patients treated with biologic agents including ustekinumab
NCT07041112	N/A	Completed	1000	Retrospective pharmacogenetic cohort study on 10-year survival of biologic therapies (including ustekinumab) in cutaneous psoriasis/PsA
NCT05535738	Phase 2/3	Recruiting	45	Suction-blistering contact dermatitis model to study how biologics modulate skin inflammation
NCT07352566	Phase 4	Not yet recruiting	10	Microdevice delivering FDA-approved AD/psoriasis drugs (including ustekinumab) directly into skin for comparative efficacy testing

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27304428	2017	RCT (Phase 2)	Experimental Dermatology	Double-blind, placebo-controlled trial in 33 moderate-to-severe AD patients assessing ustekinumab efficacy/safety
28338223	2017	RCT (Phase 2)	British Journal of Dermatology	Randomized, double-blind, placebo-controlled study of ustekinumab in Japanese patients with severe AD
33074565	2021	Systematic Review/Meta-analysis	Allergy	EAACI evidence base review of systemic treatments (including ustekinumab) for moderate-to-severe AD
29164954	2018	Systematic Review	J Dermatolog Treat	Systematic review of ustekinumab efficacy and safety specifically in AD treatment
29098604	2018	Systematic Review/Meta-analysis	Am J Clin Dermatol	Meta-analysis asking whether biologics (incl. ustekinumab) are efficacious in AD
36208443	2022	Review	Dermatologic Therapy	Review of off-label uses of ustekinumab, describing its IL-12/23 mechanism and approved indications
30850043	2019	Review	Dermatologic Clinics	Review of emerging AD treatments, contextualizing ustekinumab among newer targeted agents
33849369	2022	Real-world/Observational	J Dermatolog Treat	Real-world evidence analysis of ustekinumab effectiveness in AD patients
39987634	2025	Real-world Safety (FAERS)	Int Immunopharmacology	FDA adverse event reporting system analysis of ustekinumab safety in psoriasis/PsA
27745907	2017	Clinical Study	J Am Acad Dermatol	Ustekinumab in severe AD associated with down-regulation of Th2/Th22 gene expression

Germany Market Information

Ustekinumab is currently not marketed in Germany according to this evidence pack (0 authorizations on file). No BfArM license records, product names, dosage forms, or approved indication texts are available for extraction.

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug-interaction data for ustekinumab are flagged as a Blocking data gap (DG001 — missing TFDA/BfArM label) in this evidence pack, meaning a formal safety pre-assessment (S1) cannot yet be performed.

Conclusion and Next Steps

Decision: Hold

Rationale: Efficacy evidence for ustekinumab in dermatitis/atopic dermatitis is moderate (L2: two completed Phase 2 RCTs plus supportive systematic reviews), but a Blocking data gap on official safety labeling (DG001) prevents completion of the S1 safety pre-assessment, and the drug currently has no marketing authorization in Germany.

To proceed, the following is needed:

TFDA/BfArM package insert (warnings, contraindications) — required to clear the Blocking gap (DG001)
Confirmed mechanism of action from DrugBank API (DG002)
Formal drug-drug interaction (DDI) data
Clarification of German regulatory pathway, since the drug is not currently marketed there
Reconciliation of mixed efficacy signals across the AD trials/reviews (some show only modest benefit vs. placebo) before advancing to later decision stages
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.